Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.390 +0.030 (+1.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,539,615
Open 2.370
Bid (Size) 2.380 (50)
Ask (Size) 2.400 (2)
Prev. Close 2.360
Today's Range 2.350 - 2.410
52wk Range 1.830 - 7.480
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks
Here's a look at the most heavily shorted stocks in the market as investors look for the next Beyond Meat. 
Via Benzinga
Biotech Breakouts: 3 Stocks With Massive Upside Potential
Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential 
Via MarketBeat

Performance

YTD
-7.0%
-7.0%
1 Month
-10.5%
-10.5%
3 Month
-20.1%
-20.1%
6 Month
-11.2%
-11.2%
1 Year
-31.5%
-31.5%

More News

Read More
ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals
Via Stocktwits
Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts
Via Stocktwits
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
From ImmunityBio, Inc.
Via Business Wire
What's Going On With ImmunityBio Shares Tuesday?
Via Benzinga
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients
From ImmunityBio, Inc.
Via Business Wire
IBRX Sales Soar 2,540%
Via The Motley Fool
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
From ImmunityBio, Inc.
Via Business Wire
LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper
Via Benzinga
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via Investor Brand Network
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
Via FinancialNewsMedia
Topics Death
UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
From ImmunityBio, Inc.
Via Business Wire
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
From ImmunityBio, Inc.
Via Business Wire
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The Upside
Via Stocktwits
Foot Locker And Archer Aviation Are Among Top 8 Mid-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio?
Via Benzinga
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
From ImmunityBio, Inc.
Via Business Wire

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?
Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
What exchange does ImmunityBio, Inc. - Common Stock trade on?
ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 2.390
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 10/23/25 04:00 PM ET
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 934.86M
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 935M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.